76 207

Cited 2 times in

Prospective controlled protocol for three months steroid withdrawal with tacrolimus, basiliximab, and mycophenolate mofetil in renal transplant recipients

Authors
Oh, CK; Kim, SJ; Kim, JH; Lee, JH
Citation
Journal of Korean medical science, 27(4):337-342, 2012
Journal Title
Journal of Korean medical science
ISSN
1011-89341598-6357
Abstract
During the past few years, new immunosuppressants, such as tacrolimus, mycophenolate mofetil (MMF) and basiliximab, have been shown to successfully decrease the incidence of acute rejection, possibly acting as potent substrates for safe steroid withdrawal. Therefore, clinical outcome of 3 months steroid withdrawal, while using the above immunosuppressants, was analyzed. Clinical trial registry No. was NCT 01550445. Thirty de novo renal transplant recipients were enrolled, and prednisolone was slowly withdrawn 3 months post-transplantation by 2.5 mg at every two weeks, until 8 weeks. During steroid withdrawal, 10 patients (30.0%) discontinued the protocol and they were maintained on steroid treatment. Among 20 steroid free patients, 8 patients (40.0%) re-started the steroid within 12 months post-transplantation. By the study endpoint, 12 (40%) recipients did not take steroid and survival of patients and grafts was 100%. In conclusion, in kidney transplant patients, 3 months steroid withdrawal while taking tacrolimus, basiliximab and mycophenolate mofetil was not associated with increased mortality or graft loss. Despite various causes of failure of steroid withdrawal during the follow-up period, it is a strategy well advised for kidney transplant recipients with regard to long-term steroid-related complications.
MeSH terms
AdultAnti-Inflammatory Agents/*therapeutic useAntibodies, Monoclonal/therapeutic useBlood Urea NitrogenCholesterol/bloodCreatinine/bloodFemaleGraft Rejection/mortality/*prevention & controlHumansImmunosuppressive Agents/*therapeutic use*Kidney TransplantationMaleMiddle AgedMycophenolic Acid/analogs & derivatives/therapeutic usePrednisolone/*therapeutic useRecombinant Fusion Proteins/therapeutic useTacrolimus/therapeutic use
DOI
10.3346/jkms.2012.27.4.337
PMID
22468094
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
AJOU Authors
오, 창권이, 종훈
Full Text Link
Files in This Item:
337-342.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse